Patients with CRS resulting from CART therapy have elevated levels of IL-2, IL-5, IL-6, IL-10, and particularly, IFN-γ, early on during CRS, which then returned to baseline by 2–3 days (1–3). The gene discussed is IL5; the disease is congenital rubella syndrome.